Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanny Al-Samkari

Showing results (21-30 of 200) with videos related to

Pageof 20
Sort By:
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|February 26, 2019
Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational StudiesHanny Al-Samkari
JAMA|August 6, 2025
Ferric Carboxymaltose in Heart Failure With Iron DeficiencyHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|April 21, 2022
Doxycycline for bleeding in hereditary hemorrhagic telangiectasia: When low-hanging fruit meets inconvenient dataHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|August 26, 2021
Recognition and management of vascular lesions in von Willebrand diseaseHanny Al-Samkari
American Journal of Hematology|July 23, 2024
Mitapivat for phosphofructokinase deficiencyHanny Al-Samkari
Research and Practice in Thrombosis and Haemostasis|February 23, 2023
COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panicHanny Al-Samkari
Pediatric Blood & Cancer|November 14, 2024
Mitapivat for Acquired Pyruvate Kinase DeficiencyHanny Al-Samkari
American Journal of Hematology|August 6, 2024
2025 update on clinical trials in immune thrombocytopeniaHanny Al-Samkari
Journal of Internal Medicine|July 3, 2026
Patients with hereditary hemorrhagic telangiectasia have significantly reduced overall survival-And likely by a greater magnitude than we realizeHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|April 30, 2021
Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancyNathan Watson, Hanny Al-Samkari
Pageof 20

Showing results (21-30 of 200) with videos related to

Sort By:
Pageof 20
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|February 26, 2019
Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational StudiesHanny Al-Samkari
JAMA|August 6, 2025
Ferric Carboxymaltose in Heart Failure With Iron DeficiencyHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|April 21, 2022
Doxycycline for bleeding in hereditary hemorrhagic telangiectasia: When low-hanging fruit meets inconvenient dataHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|August 26, 2021
Recognition and management of vascular lesions in von Willebrand diseaseHanny Al-Samkari
American Journal of Hematology|July 23, 2024
Mitapivat for phosphofructokinase deficiencyHanny Al-Samkari
Research and Practice in Thrombosis and Haemostasis|February 23, 2023
COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panicHanny Al-Samkari
Pediatric Blood & Cancer|November 14, 2024
Mitapivat for Acquired Pyruvate Kinase DeficiencyHanny Al-Samkari
American Journal of Hematology|August 6, 2024
2025 update on clinical trials in immune thrombocytopeniaHanny Al-Samkari
Journal of Internal Medicine|July 3, 2026
Patients with hereditary hemorrhagic telangiectasia have significantly reduced overall survival-And likely by a greater magnitude than we realizeHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|April 30, 2021
Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancyNathan Watson, Hanny Al-Samkari
Pageof 20